We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Oriental College of Pharmacy, Sanpada, Navi Mumbai.
Over the past decade, the integration of three-dimensional (3D) printing into pharmaceutical sciences has emerged as a transformative approach for drug development and personalized medicine. Initially developed for rapid industrial prototyping, 3D printing has evolved into a versatile tool capable of fabricating customized, complex, and multi-functional drug delivery systems. The FDA’s 2015 approval of Spritam (levetiracetam), the world’s first 3D-printed oral drug, marked a pivotal moment, validating the clinical potential of additive manufacturing in the pharmaceutical sector. 3D printing enables the layer-by-layer construction of dosage forms with intricate geometries and tailored drug release kinetics. Techniques such as fused deposition modelling (FDM), inkjet printing, stereolithography (SLA), and semi-solid extrusion (SSE) have been adapted for pharmaceutical use, offering unique benefits regarding material compatibility, resolution, and scalability. These innovations have enabled the development of orodispersible tablets, polypills, pediatric and geriatric formulations, and implantable drug systems. Recent advances emphasize drug-excipient compatibility, print resolution, reproducibility, and overcoming thermal stability and post-processing challenges. The incorporation of AI-based formulation modeling, 4D printing (dynamic structures), and bioprinting of tissues and scaffolds marks the frontier of pharmaceutical innovation. Challenges include scaling production, ensuring GMP compliance, and validating digital workflows. Regulatory bodies such as the FDA and EMA are actively working on integrating these technologies within regulatory frameworks. In conclusion, the past ten years have highlighted 3D printing’s potential to revolutionize pharmaceutical manufacturing, particularly in personalized medicine. As technological, regulatory, and material science barriers are addressed, 3D printing is poised to become integral to the pharmaceutical industry’s future.
Pharmaceutical printing encompasses printing technologies used in drug product manufacturing and packaging. This includes marking tablets, capsules, and labels, and plays vital roles in product identification, patient compliance, traceability, and anti-counterfeiting. Early uses of pharmaceutical printing include imprinting identification codes or dosage details on dosage forms, reducing medication errors. Inkjet, laser, and pad printing have evolved into high-resolution digital printing capable of handling small, complex surfaces. In packaging, essential information—such as drug name, dosage, batch number, and expiry date—is printed, often with barcodes or QR codes, enhancing inventory tracking and safety. Regulatory authorities enforce stringent guidelines for compliance and public safety. The most transformative development in pharmaceutical printing has been the use of 3D printing to manufacture drug dosage forms with precise control over shape, dosage, and release profile. With the FDA approval of Spritam in 2015, 3D printing became a new frontier in personalized medicine. 3D printing builds objects from digital models, offering unmatched flexibility. Unlike traditional manufacturing, it supports rapid prototyping and personalized therapies with complex drug release behaviors—marking a new era in pharmaceutical care.
A Brief History of 3D Printing
Early Developments (1980s)
The concept emerged in 1981 with Dr. Hideo Kodama’s proposal of UV-cured photopolymer printing. The breakthrough came in 1984 when Charles Hull invented stereolithography (SLA), founding 3D Systems and introducing the STL file format, still in use today.
1990s: Expansion
This decade saw the rise of techniques like:
3D printing remained costly, largely confined to industrial prototyping.
2000s: Accessibility
Open-source initiatives like the RepRap project and patent expirations (e.g., FDM in 2009) led to reduced costs and widespread adoption, including in small businesses and education.
2010s: Industry Adoption
Applications expanded across:
3D printing gained political attention and became integral to innovation.
2020s: Strategic Use
Key developments include:
Now, 3D printing is a foundational element of Industry 4.0.
Innovations in 3D Printing for Pharmaceutical Formulations
Personalized Medicine
Techniques like FDM and inkjet printing enable dose tailoring for individual patients. Polypills can combine multiple APIs with distinct release profiles (e.g., captopril and nifedipine).
Complex Drug Delivery
Technologies like SLS and SSE allow construction of porous structures and hydrogels for immediate, sustained, or pulsatile release.
Novel Dosage Forms
Beyond tablets, 3D printing supports films, patches, and implants. Inkjet methods can print proteins (e.g., lysozyme) for mucosal delivery.
Regulatory & Commercial Progress
FDA-approved products like Triastek’s T19 and companies like FabRx show commercial viability. AI integration is also improving formulation modeling.
Sustainability
Using biodegradable materials (e.g., PVA) and on-demand production reduces environmental footprint.
Challenges in 3D Printing for Pharmaceuticals
Regulatory & Legal
Material Limitations
Technical & Economic Barriers
Software & Security
Patient Acceptance
Medical Benefits of 3D Printing
Clinical Examples:
Types of 3D Printing in Pharmaceuticals
|
Technique |
Principle |
Materials |
Applications |
|
FDM |
Extrusion of heated filaments |
PVA, PLA, HPC |
Polypills, chewables |
|
Inkjet |
Droplet deposition |
API solutions |
Oral films, precision dosing |
|
Binder Jetting |
Binder fuses powder |
Lactose, ethanol binders |
Fast-melt tablets |
|
SLA |
UV-curing resin layers |
Photopolymers |
Scaffolds, implants |
|
SLS |
Laser sinters powders |
Polymer blends |
Controlled-release tablets |
|
SSE |
Semi-solid extrusion |
Hydrogels, waxes |
Patches, thermolabile drugs |
From Lab Scale to Industry
Lab-Scale Applications
Industrial Scale Challenges
Supporting Advancements
Industrial Use Cases:
SUMMARY
3D printing is revolutionizing pharmaceutical formulation by enabling personalized, on-demand, and complex drug therapies. While numerous advances have been made—from regulatory approval to commercial production—significant barriers remain, including material limitations, regulatory gaps, and scalability. However, collaborative innovation across pharma, engineering, and regulatory domains promises a transformative future. With continued research and integration into digital health frameworks, 3D printing is set to become a cornerstone of modern, personalized medicine.
REFERENCES
Satyam Sharma, Dr. Sudha Rathod, Anjali Rai, Pharmaceutical Formulations Using 3D Printing: Advances and Challenges, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 7, 2066-2072. https://doi.org/10.5281/zenodo.15921829
10.5281/zenodo.15921829